Russia Develops mRNA-based Cancer Vaccine
Developed by National Medical Research Radiological Centre and Engelhardt Institute.
Three years of preclinical studies confirmed safety and personalized mRNA based on patient RNA.
Preclinical animal models showed 60-80% tumor reduction, early human data.
Phase I trial with 48 volunteers showed low toxicity, no serious side effects.
Approval needed before patients can receive it; larger trials needed for efficacy.
UK and US researchers are also developing cancer vaccines.
EnteroMix uses four re-engineered viruses; BioNTech, Moderna, Merck target different cancers.
1 week ago